32.53
price down icon1.48%   -0.49
pre-market  プレマーケット:  32.13   -0.40   -1.23%
loading
前日終値:
$33.02
開ける:
$33
24時間の取引高:
1.45M
Relative Volume:
0.95
時価総額:
$5.29B
収益:
$1.51B
当期純損益:
$333.35M
株価収益率:
16.68
EPS:
1.95
ネットキャッシュフロー:
$315.22M
1週間 パフォーマンス:
-3.98%
1か月 パフォーマンス:
-5.24%
6か月 パフォーマンス:
+12.83%
1年 パフォーマンス:
+19.42%
1日の値動き範囲:
Value
$32.24
$33.48
1週間の範囲:
Value
$32.05
$34.45
52週間の値動き範囲:
Value
$22.90
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
名前
Alkermes Plc
Name
セクター
Healthcare (1165)
Name
電話
00-353-1-772-8000
Name
住所
CONNAUGHT HOUSE, DUBLIN 4
Name
職員
1,800
Name
Twitter
@alkermes
Name
次回の収益日
2024-10-24
Name
最新のSEC提出書
Name
ALKS's Discussions on Twitter

ALKS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
32.53 5.29B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
161.91 72.50B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.90 47.08B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.18 45.99B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.29 17.52B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
131.87 14.05B 612.78M -86.37M -62.91M -0.87

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-13 開始されました RBC Capital Mkts Sector Perform
2025-03-04 アップグレード UBS Sell → Neutral
2025-02-11 開始されました Deutsche Bank Buy
2024-11-05 アップグレード Stifel Hold → Buy
2024-06-17 開始されました TD Cowen Buy
2024-03-19 開始されました Robert W. Baird Outperform
2024-02-20 ダウングレード UBS Neutral → Sell
2023-11-20 再開されました JP Morgan Neutral
2023-10-24 アップグレード Evercore ISI In-line → Outperform
2023-10-17 開始されました UBS Neutral
2022-11-03 アップグレード Piper Sandler Neutral → Overweight
2022-10-14 アップグレード BofA Securities Underperform → Neutral
2022-08-16 開始されました Piper Sandler Neutral
2022-04-22 再開されました Goldman Buy
2022-04-20 開始されました Goldman Buy
2022-01-27 アップグレード Cantor Fitzgerald Hold → Overweight
2021-12-01 開始されました Citigroup Neutral
2021-10-07 アップグレード Jefferies Hold → Buy
2021-09-02 ダウングレード BofA Securities Neutral → Underperform
2020-10-15 アップグレード Mizuho Neutral → Buy
2020-07-30 ダウングレード Goldman Neutral → Sell
2020-02-14 ダウングレード BofA/Merrill Buy → Neutral
2020-02-14 繰り返されました H.C. Wainwright Neutral
2020-02-14 ダウングレード JP Morgan Overweight → Neutral
2020-02-06 開始されました Mizuho Neutral
2020-01-31 アップグレード Wolfe Research Underperform → Peer Perform
2019-09-05 アップグレード Morgan Stanley Underweight → Equal-Weight
2019-07-15 アップグレード Goldman Sell → Neutral
2019-05-31 開始されました H.C. Wainwright Neutral
2019-05-01 ダウングレード Citigroup Buy → Neutral
2018-12-19 ダウングレード Goldman Neutral → Sell
2018-12-14 開始されました Wolfe Research Underperform
2018-12-13 ダウングレード Credit Suisse Outperform → Underperform
2018-11-05 開始されました Piper Jaffray Neutral
2018-08-07 開始されました Stifel Hold
2018-06-21 ダウングレード Morgan Stanley Equal-Weight → Underweight
2018-06-06 開始されました B. Riley FBR, Inc. Buy
2018-05-16 アップグレード Citigroup Neutral → Buy
2018-05-11 開始されました BofA/Merrill Buy
すべてを表示

Alkermes Plc (ALKS) 最新ニュース

pulisher
02:19 AM

Nanotechnology Drug Delivery Market Exclusive Trends Analysis - openPR.com

02:19 AM
pulisher
Apr 01, 2025

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - Sharecast News

Apr 01, 2025
pulisher
Apr 01, 2025

Alkermes Announces Initiation Of Vibrance-3 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Idiopathic Hypersomnia - MarketScreener

Apr 01, 2025
pulisher
Mar 29, 2025

(ALKS) Trading Report - news.stocktradersdaily.com

Mar 29, 2025
pulisher
Mar 27, 2025

Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

What 5 Analyst Ratings Have To Say About Alkermes - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PR Newswire

Mar 27, 2025
pulisher
Mar 27, 2025

Cibc World Markets Corp Buys New Shares in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Mar 27, 2025
pulisher
Mar 26, 2025

Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? - MSN

Mar 26, 2025
pulisher
Mar 25, 2025

Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha

Mar 25, 2025
pulisher
Mar 25, 2025

Liposomal Drug Delivery Market Detailed In New Research Report - openPR.com

Mar 25, 2025
pulisher
Mar 21, 2025

First Week of November 21st Options Trading For Alkermes (ALKS) - Nasdaq

Mar 21, 2025
pulisher
Mar 20, 2025

Controlled Release Drug Delivery Market to Witness Massive - openPR.com

Mar 20, 2025
pulisher
Mar 19, 2025

Alkermes price target raised to $35 from $34 at BofA - MSN

Mar 19, 2025
pulisher
Mar 18, 2025

Where are the Opportunities in (ALKS) - news.stocktradersdaily.com

Mar 18, 2025
pulisher
Mar 15, 2025

Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com

Mar 15, 2025
pulisher
Mar 14, 2025

Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 14, 2025
pulisher
Mar 14, 2025

Alkermes PLC Reports Q4 Revenue of $430 Million, Beating Estimat - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Alkermes (NASDAQ:ALKS) shareholders have earned a 19% CAGR over the last five years - Simply Wall St

Mar 14, 2025
pulisher
Mar 13, 2025

Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

RBC Capital Initiates Coverage of Alkermes (ALKS) with Sector Perform Recommendation - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

S&P 500 Futures Drop in Premarket Trading; Alkermes, Intel Lead - Barron's

Mar 13, 2025
pulisher
Mar 13, 2025

Alkermes initiated with a Sector Perform at RBC Capital - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Charles Schwab Investment Management Inc. Sells 38,088 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Alkermes to Participate in Upcoming Investor Conferences - GuruFocus.com

Mar 12, 2025
pulisher
Mar 11, 2025

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times

Mar 11, 2025
pulisher
Mar 09, 2025

Alkermes Plc to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 09, 2025

Alkermes plc (NASDAQ:ALKS) Shares Bought by Smartleaf Asset Management LLC - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

Proficio Capital Partners LLC Buys New Stake in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

(ALKS) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 08, 2025
pulisher
Mar 08, 2025

What is Zacks Research’s Estimate for Alkermes Q1 Earnings? - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Zacks Research Predicts Alkermes FY2027 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

UBS Group Upgrades Alkermes (NASDAQ:ALKS) to Neutral - MarketBeat

Mar 07, 2025
pulisher
Mar 06, 2025

Y Intercept Hong Kong Ltd Invests $413,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Mar 06, 2025
pulisher
Mar 05, 2025

UBS Upgrades Alkermes (ALKS) - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Bank of New York Mellon Corp Has $61.45 Million Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Alkermes (NASDAQ:ALKS) Upgraded to Neutral at UBS Group - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

UBS Upgrades Alkermes to Neutral From Sell, $38 Price Target -March 04, 2025 at 08:27 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Alkermes upgraded to Neutral from Sell at UBS - TipRanks

Mar 04, 2025
pulisher
Mar 01, 2025

Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey

Mar 01, 2025
pulisher
Mar 01, 2025

New York State Common Retirement Fund Increases Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

Ieq Capital LLC Acquires New Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Alkermes VP Samuel Parisi sells $65,892 in shares - Investing.com India

Feb 28, 2025
pulisher
Feb 28, 2025

Alkermes VP Samuel Parisi sells $65,892 in shares By Investing.com - Investing.com UK

Feb 28, 2025
pulisher
Feb 28, 2025

Illinois Municipal Retirement Fund Sells 11,878 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Alkermes plc (NASDAQ:ALKS) is HealthInvest Partners AB's 10th Largest Position - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

C WorldWide Group Holding A S Purchases Shares of 250,000 Alkermes plc (NASDAQ:ALKS) - MarketBeat

Feb 27, 2025

Alkermes Plc (ALKS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$97.93
price up icon 0.34%
$8.60
price down icon 1.26%
$107.00
price down icon 3.25%
$306.88
price down icon 0.45%
$131.87
price down icon 0.04%
大文字化:     |  ボリューム (24 時間):